Current Report Filing (8-k)
May 26 2016 - 8:51AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________
FORM 8-K
___________
CURRENT REPORT
Pursuant
To Section 13 OR 15(d) Of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 26, 2016
FUTUREWORLD
CORP.
(Exact name of registrant as specified in charter)
Delaware
|
000-1273988
|
81-0562883
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(IRS. Employer Identification No.)
|
|
|
|
FutureWorld Corp.
10901 Roosevelt Blvd, 1000c
Saint Petersburg, Florida
|
|
33716
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(727) 474-1816
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
FORWARD LOOKING STATEMENTS
This Form 8-K and other reports filed by Registrant from
time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward
looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management
as well as estimates and assumptions made by Registrant's management. When used in the filings the words "anticipate",
"believe", "estimate", "expect", "future", "intend", "plan" or the
negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward looking
statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties,
assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses
that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions
prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Although Registrant believes that the expectations reflected
in the forward looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend
to update any of the forward-looking statements to conform these statements to actual results.
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
FutureWorld announces today that on May 20, 2016, the Company
has elected Dr. Bobban Subhadra as the Chief Technology and Operation Officer at Bioceutical Sciences, effective June 1, 2016.
Dr. Bobban Subhadra core expertise is in drug target discovery and new drug applications for various indications. He works with
early-stage biotech companies to develop and commercialize core platform technologies.
Dr. Subhadra has conducted his doctoral studies in Microbiology
and Immunology at School of Medicine, University of New Mexico. After graduating he studied the role of neuroserpin, tissue plasminogen
activator, and thyroid hormone in synaptic plasticity and Alzheimer’s disease in mouse models. He has published extensively
in prestigious journals including Nature, Science, and Neurochemistry International. With his core expertise in immunology and
biochemistry and with 10+ years of industry R & D experience, he has developed numerous patented technologies and products
for biochemical, biofuel, and pharmaceutical companies. More recently, as the Director of R & D at Quorum Innovations, he developed
and commercialized numerous microbiome technologies.
Dr. Bobban Subhadra and his team at Bioceutical Sciences
will focus on the creation of a potential pharmaceutic drug with multiple technologies incorporated into the drug delivery system
such as creating hydrophobic a nanoparticle surrounded by a hydrophilic Nano-capsule similar to what liposomal technology can do
but with improved efficiency for cellular integration using specifically formulated antigens and improved systemic coverage when
implemented into a system; the focus of the drug in a biological system will be determined with future research but has established
theoretical applications such as neuropathic pain, esophagitis, and immune enhancement to name a few. With Dr. Bobban Subhadra
leading the scientific endeavor, pre-clinical and clinical trials will be highly optimized and organized testing the hypotheses
of each independent variable in the most unbiased fashion. The scope of the drug is multifaceted with focuses in: the method of
delivery into biological systems, the percentage of effectiveness, and the explorative concerns regarding the system integration
of the drug. With the completion of the method of delivery technology for this current drug, Bioceutical Sciences’ primary
research team can effectively focus on technology for the drug’s application and the drug’s future classification.
FutureWorld is preparing Bioceutical Sciences for the ensuing
spin-off.
The
FutureWorld Facebook Page (https://www.facebook.com/futureworldcorp)
The Bioceutical Sciences Facebook Page (https://www.facebook.com/
bioceuticalsciences)
The FutureWorld Twitter Feed (https://twitter.com/futureworldinc)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
FutureWorld Corp.
/s/ Sam Talari
Sam Talari
Principal Executive Officer
Dated: May 26, 2016
FutureWorld (CE) (USOTC:FWDG)
Historical Stock Chart
From May 2024 to Jun 2024
FutureWorld (CE) (USOTC:FWDG)
Historical Stock Chart
From Jun 2023 to Jun 2024